Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Perrigo company plc | Mind Blowing Facts

3 Dividend Stocks to Buy Now With Yields of About 4% or More

Three dividend stocks, Kimco Realty, Perrigo Company, and Permian Resources, are highlighted as attractive options for investors seeking steady income, with yields of 3.9% or more and strong fundamentals across the real estate, healthcare, and energy sectors.

Barchart · Nov 26, 2024

3 Lucrative Pharma Stocks to Diversify Your Investments

The pharma industry’s resilience and long-term prospects are driven by rising healthcare demand, an enhanced focus on precision medicines, and technological advancements. Hence, let’s take a look at pharma stocks Perrigo Company (PRGO), Amneal Pharmaceuticals (AMRX), and Supernus Pharmaceuticals (SUPN), which could diversify your investments. Read on….

StockNews.com · Apr 9, 2024

3 Pharma Stocks to Consider for March Gains

The pharmaceutical industry is experiencing rapid growth due to rising healthcare spending, an aging population, several technological advancements, and a favorable regulatory environment. Thus, it could be ideal to invest in quality pharma stocks Perrigo (PRGO), OptiNose (OPTN), and Teva Pharmaceutical (TEVA) for solid gains. Keep reading….

StockNews.com · Feb 29, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Bolster Your Portfolio with These 3 Pharma Stock Buys

The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences…

StockNews.com · Feb 15, 2024

Perrigo Shares Pop On Raised FY22 Guidance Surpassing Consensus Estimates

Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall. Adjusted EPS decreased 34% to $0.33, as higher sales…

Benzinga · May 11, 2022

Perrigo Clocks 5% Sales Growth In Q4, Bottom-Line Surpass Expectation

Perrigo Company plc (NYSE: PRGO)

Benzinga · Mar 1, 2022

Coverage From

Organisations

Medical Pharmaceuticals

ACADIA Pharmaceuticals Inc

15 stories

Teva Pharmaceutical Industries Limited

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Oil

37,084 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.